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Background: Glutamine (GLN) has been reported to improve clinical and experimental sepsis outcomes. However,
the mechanisms underlying the actions of GLN remain unclear, and may depend upon the route of GLN administration
and the model of acute lung injury (ALI) used. The aim of this study was to investigate whether short-term GLN
supplementation had an ameliorative effect on the inflammation induced by direct acid and lipopolysaccharide
(LPS) challenge in mice.
Methods: Female BALB/c mice were divided into two groups, a control group and a GLN group (4.17% GLN
supplementation). After a 10-day feeding period, ALI was induced by intratracheal administration of hydrochloric acid
(pH 1.0; 2 mL/kg of body weight [BW]) and LPS (5 mg/kg BW). Mice were sacrificed 3 h after ALI challenge. In this early
phase of ALI, serum, lungs, and bronchoalveolar lavage fluid (BALF) from the mice were collected for further analysis.
Results: The results of this study showed that ALI-challenged mice had a significant increase in myeloperoxidase
activity and expression of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α in the lung compared with
unchallenged mice. Compared with the control group, GLN pretreatment in ALI-challenged mice reduced the levels
of receptor for advanced glycation end-products (RAGE) and IL-1β production in BALF, with a corresponding decrease
in their mRNA expression. The GLN group also had markedly lower in mRNA expression of cyclooxygenase-2 and
NADPH oxidase-1.
Conclusions: These results suggest that the benefit of dietary GLN may be partly contributed to an inhibitory
effect on RAGE expression and pro-inflammatory cytokines production at an early stage in direct acid and
LPS-induced ALI in mice.
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InflammationBackground
Acute respiratory distress syndrome (ARDS) is often seen
in critically ill patients, and increases their risk of second-
ary bacterial pneumonia due to direct gastric fluid reflux,
bacterial pneumonia, and systemic sepsis [1]. Inflammatory
cytokines can recruit inflammatory cells from the blood
and increase the permeability of the alveolar–capillary* Correspondence: cherry85@mail.chna.edu.tw
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reproduction in any medium, provided the ormembrane after an acute lung injury (ALI) challenge [2].
ALI is characterized by significant oxidative stress and in-
flammation in the lung, which can contribute to cellular
injury [3,4].
The receptor for advanced glycation end-products (RAGE)
plays a critical role in the pathogenesis of direct acid or
lipopolysaccharide (LPS)-induced ALI, and obstruction of
RAGE signaling has a protective effect against ALI [5].
RAGE was markedly increased in bronchoalveolar lavage
fluid (BALF) in a dose-dependent manner in direct acid
(pH 1.0)-induced ALI [6]. RAGE has been implicated asl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Composition of test dietsa
Control GLN
(g/kg diet)
Corn starch 449.5 457.8
Casein 200 150
L-glutamine (GLN)b - 41.7
Sucrose 100 100
Soybean oila 150 150
Alphacel non-nutritive bulk (fiber) 50 50
AIN-93G mineral mixture 35 35
AIN-93G vitamin mixture 10 10
L-Cystine 3 3






aOur test diets were 15% high fat diets that modified from the AIN-93G
standard formula.
bThe dose of GLN supplement was provided 25% of total amino acid nitrogen.
Both of diets were isonitrogenous.
cThe two diets were isocaloric.
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as tumor necrosis factor (TNF)-α or interleukin (IL)-1β
[6,7]. RAGE is considered a useful indicator of early
stage ALI in alveolar epithelial type I cell injury, which
correlated with the severity of lung damage [8]. RAGE–
ligand interactions could result in the activation of nuclear
factor (NF)-κB and caused subsequent serial immune–
inflammatory processes [9].
Additionally, a previous report indicated that enhanced
oxidative stress was often observed in endotoxin-induced
ALI [3]. Selective inducible nitric oxide synthase (iNOS)
inhibition by a NOS inhibitor was effective in reducing
TNF-α, IL-6, and nitrite/nitrate levels in BALF by acid as-
piration in rats [10]. Antioxidant N-acetylcysteine (NAC)
treatment protected the lungs from stress in the first 12 h
after lipopolysaccharide (LPS) administered intratracheally
(IT) and also decreased the mRNA expression of NF-κB,
IL-6, TNF-α, and cyclooxygenase (COX)-2 inhibitors [11].
Thus, inhibition of oxidative stress is considered a poten-
tial strategy for ameliorating direct lung injury by LPS or
acid challenge.
Glutamine (GLN) is a conditionally essential amino acid
during critical illness and injury. GLN has been shown
to improve clinical and experimental sepsis outcomes,
owing to its anti-inflammatory and antioxidative proper-
ties [12,13]. Results of recent studies indicate that a single
intravenous dose of GLN supplementation ameliorated
lung and kidney injury and increased survival in a
cecal ligation and puncture (CLP)-induced sepsis model
by inhibition of the high-mobility group box protein-1
(HMGB-1)-mediated pathway, which was thought to be a
late-stage mediator of systemic damage [14,15]. However,
the mechanisms underlying the actions of GLN remain
undefined, and may depend on the route of administration
and the model of ALI used.
To date, no study had definitively described the effects
of dietary GLN on IT administration of acid and LPS
induced-ALI in mice. We hypothesized that GLN may
have anti-inflammatory effects on a mouse model of direct
acid and LPS-induced ALI. To test this idea, the mRNA
and protein expression of proinflammatory cytokines and
RAGE were measured. We aimed to determine whether
short-term GLN supplementation has a protective effect
in the early stages of injury.
Methods
Animals and diets
Six-week-old female BALB/c mice (body weight [BW],
17–20 g), purchased from the Laboratory Animal Center
of BioLASCO (Taipei, Taiwan), were housed individually in
stainless steel wire cages in a temperature- and humidity-
controlled room supplied with a regular 12-h light/dark
cycle. All mice were allowed free access to a chow diet
and tap water for 7 days before the study. The protocolsfor animal care and handling were approved by the
Institutional Animal Care and Use Committee of the Chia-
Nan University of Pharmacy and Science (CN-IACUC-
101028).
Mice were randomly assigned to a control group (n = 31)
and a GLN group (n = 31). Table 1 shows the compos-
ition of the two test diets. Both diets were designed
according to the AIN-93G formula, which was modified
to contain 15% soybean oil [16]. For the GLN diet,
4.17% GLN was added to the formula, replacing casein
and providing 25% of total amino acid nitrogen. The
dose of GLN was based on previous studies indicating
that this dosage of GLN had beneficial immunomodu-
latory effects [17,18]. Both diets were isonitrogenous and
isocaloric. All mice were fed the test diets for 10 days.
Finally, 10 mice from the control and GLN groups were
sacrificed as unchallenged controls, and then the re-
mainder was given the ALI challenge. After ALI chal-
lenge, nine mice in both groups were used for survival
rate assessment. Twelve mice in both groups were killed
with intraperitoneal injections of sodium pentobarbital
(50 mg/kg) after 3 h of ALI challenge. For survival
studies, an analgesic was not provided after ALI chal-
lenge. All of the mice were housed individually in a
quiet, comfortable environment after ALI challenge. Then,
the mice were observed once every h for occurrence of
mortality.
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After 10 days of feeding, 21 mice in both groups were
weighed and anesthetized with sodium pentobarbital (in-
traperitoneal [IP] injection) before inducing ALI by acid
and LPS aspiration. The procedure for IT instillation
was described in a previous report [19]. HCl (pH 1.0, in
sterile distilled water; 2 mL/kg BW) was administered IT
to each mouse. After 5 min, LPS from Escherichia. coli
(serotype 055:B5, Sigma Aldrich Co, LLC, St. Louis,
MO, USA) was instilled IT (10 μg in 50 μL sterile saline;
5 mg/kg BW) [6,10]. Twelve mice in both groups were
sacrificed with IP injections of sodium pentobarbital
(50 mg/kg) 3 h after ALI challenge.
Tissue sampling and preparation
Blood was collected via the abdominal vena cava, and
the lung tissue was excised and weighed. The blood was
centrifuged at 3500 × g at 4°C for 10 min and the serum
was stored at -80°C for future total antioxidant system
(TAS), TNF-α, and IL-6 analysis. A small piece of lung tis-
sue (approximately 30 mg) was excised, placed in storage re-
agent (RNAfter, GeneMark Ltd, Tainan, Taiwan), and stored
at -80°C for RNA extraction and subsequent real-time poly-
merase chain reaction (PCR) analysis. The remaining sam-
ple was homogenized in an ice-cold potassium phosphate
(KP) buffer (0.01 M; pH 7.4) containing 1.15% KCl, using
a Potter–Elvehjem-type homogenizer with a Teflon pestle.
A portion of the lung homogenate was centrifuged at
15,000 × g at 4°C for 30 min, and the supernatant was
taken as the post-mitochondrial fraction (PMS) for meas-
uring the activity of antioxidative enzymes and for cyto-
kine analysis. The pellets were resuspended in ice-cold
KP buffer (50 mM phosphate buffer; pH 6.0) that
contained 0.5% hexadecyltrimethylammonium bromide
(HTAB), and were stored at -80°C for further myelo-
peroxidase (MPO) analysis.
Determination of MPO activity
The method of MPO activity analysis was modified from
that described in previous studies [20,21]. After snap freez-
ing in liquid nitrogen and thawing for three cycles, samples
were centrifuged at 14,000 × g at 4°C for 10 min. Aliquots
of the supernatants were incubated in a 50 mM KP buffer
containing 0.05% hydrogen peroxide and o-dianisidine
dihydrochloride (0.167 mg/mL). MPO activity was mea-
sured by the change in absorbance at 460 nm over 3 min,
using a spectrophotometric method. The protein content
was determined using Lowry’s method [22].
Serum TAS, lung glutathione, and antioxidative enzyme
analysis
TAS was measured using commercially available enzyme-
linked immunosorbent assay (ELISA) kits, in accordance
with the manufacturer’s instructions (Cayman ChemicalCo, Ann Arbor, MI, USA). Analysis was finally read at
450 nm in a spectrophotometer. Glutathione (GSH) con-
tent and glutathione peroxidase (GPx), glutathione re-
ductase (GR), glutathione S-transferase (GST), superoxide
dismutase (SOD), and catalase activity were measured as
described elsewhere [23,24].
BALF collection
Ten mice from both groups were used for BALF collec-
tion by bronchoalveolar lavage after ALI challenge. A
20-gauge catheter was inserted into each mouse’s tra-
chea, and 1 mL sterile saline was flushed back and forth
three times. The recovered lavage was then centrifuged
at 15, 000 × g at 4°C for 10 min [19]. The supernatant al-
iquots were stored at -80°C for further analysis of cyto-
kines and RAGE by ELISA.
Quantification of cytokines and RAGE by ELISA
Levels of IL-1β, IL-6, TNF-α, and RAGE were measured
using commercially available ELISA kits, in accordance with
the manufacturer’s instructions (eBioscience, San Diego, CA
USA and R&D Systems, Minneapolis, MN, USA). Each re-
sult was finally read at 450 nm in a spectrophotometer.
RNA isolation and mRNA detection
Total RNA was extracted from the lung immersed in stor-
age solution (RNAfter) using an illustra RNAspin Mini
RNA Isolation Kit (GE Healthcare, Buckinghamshire, UK),
according to the recommended protocol. The RNA quality
was confirmed by a 28S ribosomal RNA:18S ribosomal
RNA ratio of 2 after ethidium bromide staining. Levels of
mRNA for COX-2, iNOS, IL-1β, IL-6, RAGE, and NADPH
oxidase-1 (NOX-1), were determined by real-time PCR.
Total RNA (1 μg) was reverse-transcribed into first-strand
cDNA using 200 units of Moloney murine leukemia virus
(MMLV-RT; Promega Corp, Madison, WI, USA). PCR was
performed using 50 ng cDNA, 2 SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA, USA), and 200
nM of the primer pair. The sequences of the PCR primers
used are shown in Table 2. Amplification using 40 cycles
of two steps (95°C for 15 s and 60°C for 1 min) was per-
formed on an ABI Prism 7300HT sequence detection
system (Applied Biosystems, Foster City, CA, USA). To
confirm the amplification of specific transcripts, melting
curve profiles were produced at the end of each run.
In this assay, glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) was used as an internal control. Each value
was normalized to that of GAPDH, and then the relative
mRNA abundance was calculated by taking the normal-
ized value for the control group as 1.
Statistical analysis
The main effects of dietary GLN and ALI were evaluated
by two-way analysis of variance (ANOVA). The differences



























F, Forward; R, Reverse; COX-2, cyclooxygenase-2; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; iNOS, inducible nitric oxide synthase; IL-1β,
interleukin 1β; IL-6, interleukin 6; Nox-1, NADPH oxidase; RAGE, advanced
glycation end-products.
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tiple range test. The significance of differences between
two groups was analyzed by Student’s t-test. The statistical
significance level was set at p < 0.05. All statistical analyses
were performed using SAS software (SAS Institute Inc.,
Cary, NC, USA).
Results
Body weight gain, food intake, and lung weight
As shown in Table 3, ALI challenge reduced body weight
gain and feeding efficiency. Food intake was not changed
by GLN or ALI treatment. Lung weight and relative lung
weight increased approximately 60% and 65% by ALI chal-
lenge, respectively. These results revealed that acid and
LPS aspiration caused marked enlargement of the lung,
but there was no effect of dietary GLN supplementation.
GLN treatment had no adverse effect on growth in mice.Serum TAS, GSH, and antioxidative enzyme activity
No significant differences in serum TAS, lung GSH, and
superoxide dismutase (SOD) activity were observed among
all groups (Table 4). The effects of lung catalase, GR, GST,
and selenium-dependent glutathione peroxidase (Se-GPx)
were significantly reduced in the ALI groups than in
the unchallenged groups (p < 0.05). The GLN diet had
a slight effect on ALI-challenged mice, but this did
not reach statistical difference. These results revealed
that GLN had no significant benefit on enhancement
of antioxidative enzymes.Lung MPO acitivity and IL-1β, IL-6, and TNF-α
concentrations
ALI-challenged mice had a significant increase in MPO
activity and levels of IL-1β, IL-6, and TNF-α of the lung
compared with unchallenged mice (Table 5). The ameli-
orative effect of the GLN diet was noted for IL-1β and IL-6,
and this phenomenon was dependent on ALI-challenge.
GLN treatment reduced IL-1β and IL-6 expression by 39%
and 69%, respectively, compared with the control group in
ALI-challenged mice.
Serum IL-6 and TNF-α concentrations and BALF RAGE,
IL-1β, IL-6, and TNF-α levels in ALI-challenged mice
To examine the anti-inflammatory effect of GLN in
ALI-challenged mice, we measured serum cytokine con-
centrations and used BALF for further analysis. Figure 1
shows that serum TNF-α concentrations did not differ
between the control and GLN groups in ALI-challenged
mice. In the GLN group, a marked reduction in IL-6
(37%) was observed. As shown in Figure 2, BALF RAGE
and IL-1β levels were significantly lower in the GLN
group than in the control group of ALI-challenged mice.
There were no significant differences in IL-6 and TNF-α
levels between the control and GLN groups.
Lung mRNA expression in ALI-challenged mice
To further examine the effect of dietary GLN on gene ex-
pression, we measured the mRNA levels of inflammatory
cytokines, iNOS and COX-2, and the oxidant-generating
enzyme, NOX-1. As shown in Figure 3, no statistical dif-
ference in iNOS expression was seen between the two
groups. GLN treatment reduced COX-2 mRNA expres-
sion by 58% compared with the control group. The GLN
group had significantly lower mRNA levels of IL-1β and
IL-6 compared with the control group (39% and 49%, re-
spectively). RAGE mRNA was significantly decreased in
the GLN group. NOX-1mRNA was markedly lower in the
GLN group than in the control group.
Discussion
In our previous studies, we used an animal model of se-
vere ALI by both direct acid and LPS challenge for imi-
tation of clinical cases of direct gastric fluid reflux and
bacterial pneumonia. Our previous results indicated that
RAGE, TNF-α, and IL-6 expression was significantly
higher than that of the unchallenged mice at the early
stage (3 and 6 h of injury), but all mice died 48 h after
ALI challenge (data not shown). Using this severe ALI
model, we speculated that GLN could reduce the expres-
sion of these cytokines at an early stage, consequently
improving the outcome of ALI. Therefore, the aim of
the present study was to determine whether short-term
GLN supplementation had a protective effect in the early
stages of injury. The dosage of GLN was approximately
Table 3 Body weight gain, food intake, feed efficiency, and lung weight of micea
Unchallenged ALI p values from Two-way ANOVAb
Control GLN Control GLN ALI GLN ALI × GLN
Initial body weight (g) 20.0 ± 0.9 20.0 ± 0.9 20.1 ± 0.8 20.1 ± 0.8 NS NS. NS.
Body weight gain (g/d) 0.25 ± 0.09 0.21 ± 0.17 0.19 ± 0.10 0.15 ± 0.11 < 0.05 NS. NS.
Food intake (g/d) 4.24 ± 0.28 4.11 ± 0.30 4.50 ± 0.44 4.32 ± 0.84 NS. NS. NS.
Feed efficiency (%)c 5.89 ± 2.08 4.90 ± 4.36 4.06 ± 2.14 3.40 ± 2.49 < 0.05 NS. NS.
Lung weight (g) 0.15 ± 0.03 0.14 ± 0.01 0.24 ± 0.06 0.23 ± 0.04 < 0.001 NS. NS.
Relative lung weight (%)d 0.65 ± 0.10 0.60 ± 0.08 1.09 ± 0.27 1.06 ± 0.17 < 0.001 NS. NS.
aEach value represents Mean ± S.D., n = 10-12. NS., no significant difference.
bThe significance of differences among four groups were analyzed by two-way ANOVA. Values not sharing a same superscript letters in the horizontal row are
significantly different from one another by Duncan’s Multiple Range Test (P < 0.05).
cFeed efficiency (%) = 〔body weight gain (g)/food intake (g)〕 × 100.
dRelative lung weight (%) = (lung weight/body weight) × 100.
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to that previously described [25]. As shown in Table 3,
enteral GLN administration was safe and did not cause
any adverse effects on growth. The survival rate 24 h
after ALI challenge was 33% in the GLN group and 11%
in the control group (data not shown). The ameliorative
effect of GLN supplementation on the survival rate was
not complete, which may be a result of more severe injury
in this model of ALI induced by two powerful chemicals.
A study conducted by Zhou et al. [26] demonstrated that
IP LPS injection plus HCl aspiration produced significant
lung injury, compared with either LPS injection or HCl in-
stillation alone. Therefore, dietary GLN supplementation
had a beneficial effect only within 24 hours after this se-
vere ALI challenge, but in the end could not rescue sur-
vival. We will try to modify this severe ALI model by
reducing the dose of LPS/acid in next study to further ex-
plore the effect of dietary GLN on survival.
To elucidate the anti-inflammatory effect of GLN in
ALI-challenged mice, we did not analyze BALF cytokines
and lung mRNA expression in both unchallenged groups
because we found that the levels of these cytokines of
unchallenged controls were very low or undetectable inTable 4 Serum TAS, lung GSH content, and anitixoidative enz
Unchallenged
Control GLN Contro
Serum TAS (mM) 1.13 ± 0.11 1.11 ± 0.17 1.04 ± 0
GSH (μmol/g Lung) 4.57 ± 2.44 4.62 ± 2.72 3.89 ± 2
Catalase (unit/mg protein) 29.1 ± 2.4 29.1 ± 2.5 21.3 ± 2
GR (unit/g protein) 30.6 ± 3.6 31.5 ± 2.6 27.3 ± 3
GST (unit/mg protein) 0.39 ± 0.08 0.41 ± 0.08 0.28 ± 0
SOD (unit/mg protein) 3.07 ± 0.26 3.32 ± 0.24 3.23 ± 0
Se-GPx (unit/g protein) 44.8 ± 6.4 45.4 ± 9.1 37.4 ± 5
aEach value represents Mean ± S.D., n = 10-12. NS., no significant difference; GSH, gl
se-dependent glutathione peroxidase; SOD, superoxide dismutase; TAS, total antiox
bThe significance of differences among four groups were analyzed by two-way ANO
significantly different from one another by Duncan’s Multiple Range Test (P < 0.05).our previous study (data not shown). The other reason
was to reduce this experimental cost and assay load,
which caused this experimental design flaw in our stud-
ies. Therefore, the possible effects of GLN discussed
below focus on the ALI-challenged condition in mice.
There are a number of possible explanations for the pro-
tective effect of GLN against ALI during sepsis, including
enhanced expression of heat shock protein (HSP), activa-
tion of peroxisome proliferator-activated receptor (PPAR)-γ,
buffering of oxidative stress, inhibition of HMGB-1 ex-
pression, and anti-inflammatory responses [13,15]. This
model of acid and LPS introduced into the trachea led to
a direct, chemically induced, tissue-level injury of the lung
in such a short time that there was no immediate mount-
ing of an immune response, as is observed in the normal
model of septic system injury. Given our results, we spec-
ulated that the key function of GLN was to reduce the in-
flammatory response by inhibiting RAGE expression and
pro-inflammatory cytokine production.
First, as shown in Figures 2A and 3E, this study demon-
strated that dietary GLN could downregulate RAGE ex-
pression in the lung. RAGE is a marker of type I cell injury
in ALI [8]. A previous report indicated that HMGB-1 wasyme activitya
ALI p values from Two-way ANOVAb
l GLN ALI GLN ALI × GLN
.07 1.07 ± 0.11 NS. NS. NS.
.99 6.42 ± 2.52 NS. NS. NS.
.1 22.3 ± 2.4 < 0.001 NS. NS.
.3 28.5 ± 2.6 < 0.05 NS. NS.
.04 0.30 ± 0.04 < 0.001 NS. NS.
.36 3.28 ± 0.47 NS. NS. NS.
.3 43.6 ± 5.4 0.05 NS. NS.
utathione; GR, glutathione reductase; GST, glutathione S-transferase; Se-GPx,
idant system.
VA . Values not sharing a same superscript letters in the horizontal row are
Table 5 Lung MPO acitivity and IL-1β, IL-6, and TNF-α concentrations of micea
Unchallenged ALI p values from Two-way ANOVAb
Control GLN Control GLN ALI GLN ALI × GLN
MPO acitivity (unit/g lung) 7.97 ± 13.5 8.27 ± 14.9 207 ± 92 195 ± 92 < 0.001 NS. NS.
IL-1β (ng/mg protein) 0.02 ± 0.01c 0.03 ± 0.02c 0.18 ± 0.1a 0.11 ± 0.05b < 0.001 NS. < 0.05
IL-6 (ng/mg protein) 0.11 ± 0.04c 0.12 ± 0.05c 1.69 ± 1.26a 0.56 ± 0.34b < 0.001 < 0.05 < 0.05
TNF-α (ng/mg protein) 0.05 ± 0.02 0.06 ± 0.03 0.26 ± 0.16 0.15 ± 0.17 < 0.001 NS. NS.
aEach value represents Mean ± S.D., n = 10-12. NS., no significant difference.
bThe significance of differences among four groups were analyzed by two-way ANOVA . Values not sharing a same superscript letters in the horizontal row are
significantly different from one another by Duncan’s Multiple Range Test (p < 0.05).
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trigger of inflammation in animal models via RAGE activa-
tion [27]. Administration of recombinant RAGE could at-
tenuate injury in LPS-induced ALI in mice [7]. Recently,
BALF RAGE was considered a sensitive indicator for direct
lung injury in acid or LPS-induced ALI in mice, particu-
larly in acid-challenged mice [7]. Yamakawa and colleagues
[28] indicated that LPS stimulation resulted in release of
RAGE into the media in a dose-dependent manner from
cultured rat alveolar epithelial cells, and verified the that
proteolysis was primarily caused by matrix metalloprotein-
ase (MMP)-3 and -13. Therefore, we also measured MMP-
3 mRNA in the lung. The GLN diet decreased relative
MMP-3 mRNA expression by 30%, but this did not reach
statistical difference (data not shown). Confirmation of
whether the mechanism by which GLN treatment causes a
decrease in RAGE expression is mediated by proteolysis is
beyond the scope of this study. According to previous re-
ports, attenuation of RAGE activation led to a decrease in
ALI severity. Thus, we suggest that dietary GLN exerted
its protective role by decreasing RAGE expression in ALI-
challenged mice.
Second, we found that lung IL-1β and IL-6 levels were
significantly lower in the GLN group with corresponding
decreases in their mRNA expression than was observed
in the control group. We speculate that proinflammatory
cytokines such as TNF-α, IL-1β, and IL-6 were released
in the early stage of ALI challenge; in other studies, IL-6
was considered a particularly useful marker for predic-
tion of the severity of sepsis. Previous reports revealedA
Figure 1 Serum IL-6 and TNF-α concentrations of ALI-challenged mice
n = 10–12. The effect of GLN was evaluated by Student’s t-test in two ALI-ithat enteral GLN supplementation for 3 weeks decreased
lung IL-6 levels and regulated the immune response dur-
ing CLP-induced sepsis [29,30]. Thus, we propose that
GLN supplementation had an anti-inflammatory effect
against ALI challenge at an early stage.
Third, worsening oxidative stress was a possible cause
of ALI damage. To determine whether the antioxidant
properties of GLN are associated with ALI-induced oxida-
tive stress, we measured GSH and antioxidative enzymes.
The lung GSH concentration and mRNA level of γ-
glutamyl-cysteine-synthetase (data not shown) were un-
changed in the GLN group. Recent experimental data
have demonstrated that HSP70 enhancement is the main
factor responsible for the beneficial effects of GLN on ALI
during sepsis, because GLN is required for HSP gener-
ation [15,25,31]. It is unclear whether short-term dietary
GLN supplementation is sufficient to generate the level of
HSP required for buffering the acid and LPS-induced
damage. Therefore, Hsp70 expression warrants further
investigation. Interestingly, we found that mice that re-
ceived GLN supplementation showed a marked reduction
in lung COX-2 and NOX-1 mRNA. A previous study
showed that lung COX-2 expression and activity were in-
creased in acid-induced injury, and the actual role of
COX-2 varied at different stages of injury [32]. NOX-1 has
been identified as the major oxidant-generating enzyme
in neutrophils and macrophages [33]. A previous report
demonstrated that NOX-1 was responsible for more than
90% of the lipid-derived free radicals and was implicated
in lung damage in an IT LPS-induced lung injury modelB
. (A) IL-6, (B) TNF-α. Data are presented as mean ± standard deviation;
nduced groups; (*p < 0.05 vs. the control group).
Figure 2 RAGE concentrations in the BALF of ALI-challenged mice. (A) RAGE; (B) IL-1β; (C) IL-6; (D) TNF-α. Data are presented as mean ± standard
deviation; n = 10–12. The effect of GLN was evaluated by Student’s t-test in two ALI-induced groups (*p < 0.05 vs. the control group).
Figure 3 Relative mRNA levels of inflammatory genes in the lungs of ALI-challenged mice. (A) iNOS; (B) COX-2; (C) IL-1β; (D) IL-6; (E) RAGE;
(F) NOX-1. Each value was normalized to that of GAPDH, and the relative mRNA abundance was expressed as a fraction of that in the control
group and assigned a value of 1. Data are presented as mean ± standard deviation; n = 10–12. The effect of GLN was evaluated by Student’s t-test
in two ALI-induced groups (*p < 0.05 vs. the control group).
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attenuated in NOX-1 null mice (deficient in the gp91phox
and p47phox subunits of Nox) [35,36]. NOX-1 inhibitors
have been considered a potential therapy for ALI [34].
Therefore, NOX-1 inhibition might have an additional
benefit in GLN-treated mice after ALI challenge.
MPO is a useful marker of neutrophil infiltration in
different ALI models [37,38]. Our data showed that 3 h of
ALI challenge resulted in significantly higher MPO activity
than in unchallenged mice, but no abrogation effect was
caused by GLN treatment. It is possible that the selected
time point was not appropriate for GLN function, thus
the decreased effect on MPO activity was not observed in
our study, unlike previous reports [39,40]. On the other
hand, toll-like receptor 4 (TLR4) signaling was believed to
be another pathway of acid and LPS-induced ALI other
than RAGE expression. In mice treated with adenovirus-
mediated siRNA targeting the TLR4 gene, a protective
effect was shown against LPS challenge [41]. Thus,
whether TLR4 signaling was involved in the beneficial
effects of GLN remains to be explored in future studies.
Conclusions
Our results suggest that the beneficial effects of diet-
ary GLN supplementation might be partially attrib-
uted to an inhibitory effect on RAGE expression and
pro-inflammatory cytokine production at an early stage in
acid- and LPS-induced ALI.
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